Cyclerion Looking To Partner Praliciguat Despite Phase II Fail In Diabetic Nephropathy
Executive Summary
The Ironwood spinout thinks its sGC stimulator demonstrated benefit in reducing urine albumin levels in DN patients; notes data improve markedly if one outlier trial site is excluded.
You may also be interested in...
Deal Watch: AbbVie To Try Caraway’s Lysosomal Function Approach To Parkinson’s
Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.
Ironwood Ends Phase III GERD Program, Will Cut 100 Jobs
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
Cyclerion Readies For Readouts In Sickle Cell, Other Rare, Serious Diseases This Year
Spun out from Ironwood with a $175m financing, Cyclerion added Bayer and Shire veteran Andreas Busch to its management team as Chief Innovation Officer as it awaits a trio of Phase II data readouts coming this year for its sGC stimulators.